Genomics’ Ethical Gray Areas Are Harming the Developing World
By Dyna Rochmyaningsih,
Undark Magazine
| 02. 24. 2022
Since the first human genome was sequenced in the early 2000s, scientists have touted the breakthrough as a blessing to humanity — one that holds promise to promote human health and enhance medical treatment the world over. But around two decades later, the benefits of that scientific advancement have barely rippled out beyond Europe and North America. As of 2018, people of European ancestry —who represented approximately 16 percent of the world population at the time — made up 78 percent of all individuals whose genomes have ever been collected and studied.
Over the last decade or so, international studies on human population genetics have begun to expand genomic libraries to encompass regions of the Global South — including Southeast Asia, where I am a science reporter, and the Pacific islands. These international studies, often led by Western scientists, have contributed to a more global understanding of ancient patterns of human migration and evolution. But on some occasions, they’ve also sidestepped local regulatory agencies in the developing world, and ventured into murky research ethics terrain as a result.
A recent example...
Related Articles
By Alex Aylward, Daniel J. Fairbanks, Maria Kiladi, and Gregory Radick , Heredity | 04.20.2026
Genetics and eugenics co-evolved at the beginning of the twentieth century and remained associated through the 1940s and beyond. Early geneticists were far from unanimous in their views on eugenics; some avidly supported the movement, whereas others openly opposed it...
By Staff, GMWatch | 03.28.2026
Following a recent podcast interview we were asked whether there is any solid scientific research looking at how gene expression or molecular composition in genetically modified (GM) plants differs from conventionally bred plants. As this is an interesting and important...
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
By Ryan Cross, Endpoints News | 03.24.2026
Cathy Tie has an audacity more typical of a tech startup founder than a biotech executive. She dropped out of college to start a genetic screening company and later founded a telemedicine startup. The 29-year-old has been on two Forbes...